Printer Friendly

Global Markets for Media, Sera and Reagents in Biotechnology -- Focus on the U.S.

NEW YORK, May 31, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Markets for Media, Sera and Reagents in Biotechnology -- Focus on the U.S.

http://www.reportlinker.com/p0870805/Global-Markets-for-Media-Sera-and-Reagents-in-Biotechnology----Focus-on-the-US.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

INTRODUCTION

STUDY OBJECTIVES

BCC's goal in conducting this study is to provide an overview of the current and future characteristics of the global market for media, sera and the reagents used in biotechnology. The key objective is to present a comprehensive analysis of the current market and its future direction in the media, sera and biotechnology reagents markets as an important tool for the cell culture industry.

This report explores present and future strategies within the media and sera market, including reagents used in biotechnology. The improvisation of the market, the setbacks and the needs of the market are discussed in this report. The types of cell cultures and the products from cell culture technology are also presented in this report. The advantages and disadvantages for the use of various types of media are also covered in this report.

A detailed analysis of the cell culture industry structure has been conducted. This includes the biotechnology reagents, media and the sera used. Revenues are broken down by global region. Sales figures are estimated for the five-year period from 2011 through 2016.

Applications for the cell culture industry-media, sera and reagents used in biotechnology-are also discussed in the report, with an emphasis on the usage in the research, production and contract segments. The report also covers significant patents in each segment.

REASONS FOR DOING THIS STUDY

Demand for cell culture products, namely media, sera and reagents, is increasing, with the increasing demand for biopharmaceuticals. Cell culture, a crucial component of the life sciences industry, has witnessed major development during the past three decades. R&D spending, along with increasing competition, patent expiries, new technologies and an international marketplace are moving the cell culture process in a new direction. As cell culture technologies evolved, a number of disciplines such as cell biology, genetic engineering, protein chemistry, genomics and chemical engineering have been successfully incorporated into the cell culture field.

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strength and weaknesses of the different types of media used in light of the new technologies, growing competition and changing customer needs.

INTENDED AUDIENCE

This study contributes to the areas of market growth in the cell culture industry from the point of view of manufacturers and users. Biotechnological companies, physicians, the pharmaceutical and biopharmaceutical industries, hospitals and research institutes will find this study to be of interest.

SCOPE OF THE STUDY

The scope of this study encompasses the biotechnology, pharmaceutical and medical markets. BCC analyzes each market and its applications by its need for development of new medications through cell culture techniques, the regulatory environment, technology involved, market projections and market share. Technological issues include the latest trends and developments.

METHODOLOGY

BCC conducted a comprehensive literature search, which included technical newsletters and journals, and many other sources. Data was collected through interviews and correspondence with various analytical, chemical, pharmaceutical and biotechnical experts. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.

INFORMATION SOURCES

Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of biopharmaceuticals, and pharmaceutical companies through their production, research and contract manufacturing/research lines. Data were gathered from various industry sources. BCC spoke with officials and physicians within the industry, consulted newsletters, company literature, product literature and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.

ABOUT THE AUTHOR

The study has been carried out by a team of professionals in the biotechnology industry. The project manager for this project is Shalini S. Dewan, who holds a Master's degree in Pharmaceutical Chemistry and has more than 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC are Reagents for Chromatography; Spectroscopy, an Enduring Market; Advanced Drug Delivery Systems: Technologies and Global Markets; Orthopedic Drugs, Implants and Devices; Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry; The Dynamic Media, Sera and Reagent Market in Biotechnology; Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets; Chiral Technology: Global Markets; Autacoids and Related Drugs: Technologies and Global Markets; Contraceptives: Technologies and Global Markets; Liver Disease Treatments: The Global Market; Hormone Replacement Therapies and Other Hormone Therapies: Global Markets; Cardiovascular Medicine: Diagnostics, Drugs and Devices; and Cancer Therapies: Technologies and Global Markets.

The lead consultant for this project was Dr. Kapil A. Setia, who holds a doctoral degree in the life sciences. She has a number of research publications to her credit.

TABLE OF CONTENTS

CHAPTER ONE: INTRODUCTION 1

STUDY OBJECTIVES 1

REASONS FOR DOING THIS STUDY 1

INTENDED AUDIENCE 2

SCOPE OF THE STUDY 2

METHODOLOGY 2

INFORMATION SOURCES 2

ABOUT THE AUTHOR 3

RELATED BCC RESEARCH REPORTS 3

BCC ONLINE SERVICES 3

DISCLAIMER 4

CHAPTER TWO: EXECUTIVE SUMMARY 5

EXECUTIVE SUMMARY 5

SUMMARY TABLE GLOBAL REVENUES FROM MEDIA, SERA AND

REAGENTS USED IN THE BIOTECHNOLOGY MARKET,

THROUGH 2016 ($ MILLIONS) 6

SUMMARY FIGURE GLOBAL REVENUES FROM MEDIA, SERA AND

REAGENTS USED IN THE BIOTECHNOLOGY MARKET, 2009-2016

($ MILLIONS) 6

EXECUTIVE SUMMARY (CONTINUED) 7

CHAPTER THREE: OVERVIEW 8

DEFINITIONS 8

HISTORY 8

TABLE 1 HISTORICAL EVENTS IN CELL CULTURE DEVELOPMENT 9

TABLE 1 (CONTINUED) 10

TYPES OF CELL CULTURES 10

PRIMARY CULTURES 10

TABLE 2 ADVANTAGES AND DISADVANTAGES OF PRIMARY CELL

CULTURE 11

SECONDARY CELL CULTURE 11

CONTINUOUS CELL CULTURE 11

TABLE 3 ADVANTAGES AND DISADVANTAGES OF CONTINUOUS

CELL CULTURE 12

MORPHOLOGY OF CELLS IN CULTURE 12

FIBROBLASTIC CELLS 12

EPITHELIAL-LIKE CELLS 12

LYMPHOBLAST-LIKE CELLS 12

BASIC SYSTEMS FOR CELL CULTURE 12

TABLE 4 ADHERENT CULTURE VS SUSPENSION CULTURE 13

CELL LINE, CELL STRAIN AND TRANSFORMED CELL LINES 13

CHARACTERISTICS OF IMMORTALIZED CELL LINES 14

FACTORS AFFECTING CELL CULTURE 14

APPLICATIONS OF CELL CULTURE 15

MODEL SYSTEM 15

CANCER RESEARCH 15

VIROLOGY 15

TABLE 5 CULTURE MEDIA USED FOR THE PRODUCTION OF

VACCINES 16

TABLE 5 (CONTINUED) 17

GENETICALLY ENGINEERED PROTEINS 17

TABLE 6 POTENTIAL SOURCES OF CELL CULTURE ADDITIVES 18

Recombinant Thrombolytic Agents 19

TABLE 7 RECOMBINANT THROMBOLYTIC AGENTS 19

Recombinant Coagulation Factor 19

TABLE 8 RECOMBINANT COAGULATION FACTOR 20

Cytokines 20

Hematopoietic Growth Factors 21

Human Growth Hormones 22

Monoclonal Antibodies 22

TISSUE AND ORGAN REPLACEMENT 22

GENETIC COUNSELING 23

GENE THERAPY 23

PROBLEMS DURING CELL CULTURE 23

TOXICITY 23

MICROBIAL CONTAMINATION 23

Cross-Contamination 24

BASIC REQUIREMENTS OF CELL CULTURE 24

CELL CULTURE MEDIA 24

Basic Constituents of Media 24

Inorganic Salts 24

TABLE 9 THE ROLES OF DIFFERENT INORGANIC NUTRIENTS 25

Buffering Systems 25

Energy Source 26

Amino Acids 26

Vitamins 26

Proteins and Peptides 27

Fatty Acids and Lipids 27

Trace Elements 27

Antibiotics 28

TABLE 10 COMMONLY USED ANTIBIOTICS IN CELL CULTURES 28

Serum 29

Types of Cell Culture Media 29

Serum-Containing Media 29

TABLE 11 ADVANTAGES AND DISADVANTAGES OF SERUMCONTAINING

MEDIA 30

Serum-free Media 30

TABLE 12 ADVANTAGES AND DISADVANTAGES OF SERUM-FREE

MEDIA 31

Chemically Defined Media 31

Amino Acids 31

Carbohydrates 32

Inorganic Salts 32

Vitamins 32

Protein-Free Media 32

Selection of Cell Culture Media 33

Serum-Free Media: Reasons for Preference 33

Supplements for Serum-Free Media 33

Hormones 34

Transferrin 34

Lipids 34

Hydrolysates 35

SERUM 35

Role of Serum in Cell Culture 35

Serum Components 36

Growth Factors 36

Albumin 36

Protease Inhibitors 36

TABLE 13 NORMAL RANGE OF CONCENTRATION OF SERUM

CONSTITUENTS 36

TABLE 13 (CONTINUED) 37

Sources of Serum 37

Fetal Bovine Serum 37

Calf Serum 37

Calf Serum, Donor (Bovine) 37

Calf Serum, Newborn (Bovine) 37

Other Animal Sera 38

Chicken Serum 38

Dog Serum 38

Donor Donkey Serum 38

Donor Goat Serum 38

Donor Rat Serum 38

Rat Serum 38

Feline Serum 38

Guinea Pig Serum 39

Monkey Serum 39

Mouse Serum 39

Porcine Serum 39

Rabbit Serum 39

Sheep Serum 39

Horse Serum 39

Potential Problems with Serum 40

Serum Selection 40

CELL CULTURE REAGENTS 41

Amino Acids and Vitamins 41

Antibiotics and Antimycotics 41

Buffers 41

Cell Dissociation Agents 42

Growth Supplements 42

REGULATORY ASPECTS 42

APPROVALS OF BIOLOGICAL LICENSE APPLICATIONS 43

TABLE 14 APPROVALS OF BIOLOGICAL LICENSE APPLICATIONS,

2010 TO AUG 2011 43

TABLE 14 (CONTINUED) 44

ADMINISTRATIVE ACTIONS: BIOLOGICS 44

TABLE 15 ADMINISTRATIVE ACTIONS: BIOLOGICS, 2007 TO AUG

2011 44

TABLE 15 (CONTINUED) 45

TABLE 16 PRODUCT RECALLS, 2007 TO AUG 2011 46

TABLE 16 (CONTINUED) 47

TABLE 16 (CONTINUED) 48

LEADING MANUFACTURERS OF MEDIA 48

TABLE 17 LEADING MANUFACTURERS OF MEDIA 48

TABLE 17 (CONTINUED) 49

TABLE 17 (CONTINUED) 50

TABLE 17 (CONTINUED) 51

TABLE 17 (CONTINUED) 52

TABLE 17 (CONTINUED) 53

TABLE 17 (CONTINUED) 54

TABLE 18 LEADING MANUFACTURERS OF SERA 54

TABLE 18 (CONTINUED) 55

TABLE 18 (CONTINUED) 56

TABLE 19 LEADING MANUFACTURERS OF BIOLOGIC RESPONSE

MODIFIERS 57

TABLE 19 (CONTINUED) 58

TABLE 19 (CONTINUED) 59

TABLE 19 (CONTINUED) 60

TABLE 20 LEADING MANUFACTURERS OF CELL DISSOCIATION

REAGENTS 60

TABLE 20 (CONTINUED) 61

TABLE 21 LEADING MANUFACTURERS OF ANTIBIOTICS AND

ANTIMYCOTICS USED IN CELL CULTURE 62

TABLE 21 (CONTINUED) 63

TABLE 22 LEADING MANUFACTURERS OF OTHER REAGENTS 63

TABLE 22 (CONTINUED) 64

TABLE 22 (CONTINUED) 65

NEW DEVELOPMENTS 66

TABLE 23 NEW DEVELOPMENTS IN THE CELL CULTURE

INDUSTRY SINCE 2008 67

TABLE 23 (CONTINUED) 68

NEW DEVELOPMENTS IN APPLICATIONS 68

NEW DEVELOPMENTS IN APPLICATIONS (CONTINUED) 69

TABLE 24 NEW DEVELOPMENTS IN APPLICATION OF CELL

CULTURE 70

TABLE 24 (CONTINUED) 71

CHAPTER FOUR: GLOBAL MARKETS 72

GLOBAL MARKETS 72

GLOBAL MARKETS (CONTINUED) 73

TABLE 25 GLOBAL MARKET FOR CELL CULTURE PRODUCTS,

THROUGH 2016 ($ MILLIONS) 74

FIGURE 1 GLOBAL MARKET FOR CELL CULTURE PRODUCTS,

2009-2016 ($ MILLIONS) 74

MEDIA 75

MARKET REVENUE 76

TABLE 26 GLOBAL MARKET FOR MEDIA USED IN

BIOTECHNOLOGY BY REGION, THROUGH 2016 ($ MILLIONS) 76

FIGURE 2 GLOBAL MARKET FOR MEDIA USED IN

BIOTECHNOLOGY BY REGION, 2009-2016 ($ MILLIONS) 77

MARKET SHARES 77

TABLE 27 GLOBAL BIOTECHNOLOGY MEDIA MARKET SHARES BY

REGION, 2010 (%) 77

FIGURE 3 GLOBAL BIOTECHNOLOGY MEDIA MARKET SHARES BY

REGION, 2010 (%) 78

SERUM-FREE MEDIA AND SERUM-REQUIRING MEDIA 78

Serum-Free Media Market Revenue 79

TABLE 28 GLOBAL MARKET FOR SERUM-FREE MEDIA BY REGION,

THROUGH 2016 ($ MILLIONS) 79

FIGURE 4 GLOBAL MARKET FOR SERUM-FREE MEDIA BY REGION,

2009-2016 ($ MILLIONS) 79

Serum-Requiring Media Market Revenue 80

TABLE 29 GLOBAL MARKET FOR SERUM-REQUIRING MEDIA BY

REGION, THROUGH 2016 ($ MILLIONS) 80

FIGURE 5 GLOBAL MARKET FOR SERUM-REQUIRING MEDIA BY

REGION, 2009-2016 ($ MILLIONS) 81

POWDERED MEDIA AND LIQUID MEDIA 81

Powdered Media Market Revenue 82

TABLE 30 GLOBAL MARKET FOR POWDERED MEDIA, THROUGH

2016 ($ MILLIONS) 82

FIGURE 6 GLOBAL MARKET FOR POWDERED MEDIA, 2009-2016 ($

MILLIONS) 82

Liquid Media Market Revenue 83

TABLE 31 GLOBAL MARKET FOR LIQUID MEDIA BY REGION,

THROUGH 2016 ($ MILLIONS) 83

FIGURE 7 GLOBAL MARKET FOR LIQUID MEDIA BY REGION, 2009-

2016 ($ MILLIONS) 83

CLASSICAL AND SPECIALTY MEDIA 84

Classical Media Market Revenue 84

TABLE 32 GLOBAL MARKET FOR CLASSICAL MEDIA BY REGION,

THROUGH 2016 ($ MILLIONS) 85

FIGURE 8 GLOBAL MARKET FOR CLASSICAL MEDIA BY REGION,

2009-2016 ($ MILLIONS) 85

Specialty Media Market Revenue 86

TABLE 33 GLOBAL MARKET FOR SPECIALTY MEDIA BY REGION,

THROUGH 2016 ($ MILLIONS) 86

FIGURE 9 GLOBAL MARKET FOR SPECIALTY MEDIA BY REGION,

2009-2016 ($ MILLIONS) 86

SERA 87

MARKET REVENUE 88

TABLE 34 GLOBAL MARKET FOR SERA BY REGION, THROUGH

2016 ($ MILLIONS) 88

FIGURE 10 GLOBAL MARKET FOR SERA BY REGION, 2009-2016 ($

MILLIONS) 88

MARKET SHARES 89

TABLE 35 GLOBAL SERA MARKET SHARES BY REGION, 2010 (%) 89

FIGURE 11 GLOBAL SERA MARKET SHARES BY REGION, 2010 (%) 89

BOVINE SERA OR FETAL BOVINE SERA 90

TABLE 36 GLOBAL MARKET FOR BOVINE SERA BY REGION,

THROUGH 2016 ($ MILLIONS) 90

FIGURE 12 GLOBAL MARKET FOR BOVINE SERA BY REGION, 2009-

2016 ($ MILLIONS) 91

OTHER SERA 91

TABLE 37 GLOBAL MARKET FOR OTHER SERA BY REGION,

THROUGH 2016 ($ MILLIONS) 92

FIGURE 13 GLOBAL MARKET FOR OTHER SERA BY REGION, 2009-

2016 ($ MILLIONS) 92

REAGENTS 93

MARKET OVERVIEW 94

MARKET REVENUE 95

TABLE 38 GLOBAL MARKET FOR CELL CULTURE REAGENTS BY

REGION, THROUGH 2016 ($ MILLIONS) 95

FIGURE 14 GLOBAL MARKET FOR CELL CULTURE REAGENTS BY

REGION, 2009-2016 ($ MILLIONS) 96

MARKET SHARES 96

TABLE 39 GLOBAL CELL CULTURE REAGENT MARKET SHARES

BY REGION, 2010 (%) 96

FIGURE 15 GLOBAL CELL CULTURE REAGENT MARKET SHARES

BY REGION, 2010 (%) 97

BIOLOGICAL RESPONSE MODIFIERS 97

TABLE 40 GLOBAL MARKET FOR BIOLOGICAL RESPONSE

MODIFIERS BY REGION, THROUGH 2016 ($ MILLIONS) 97

FIGURE 16 GLOBAL MARKET FOR BIOLOGICAL RESPONSE

MODIFIERS BY REGION, 2009-2016 ($ MILLIONS) 98

Growth Factors 98

TABLE 41 GLOBAL MARKET FOR GROWTH FACTORS BY REGION,

THROUGH 2016 ($ MILLIONS) 99

FIGURE 17 GLOBAL MARKET FOR GROWTH FACTORS BY REGION,

2009- 2016 ($ MILLIONS) 99

Cytokines 99

TABLE 42 GLOBAL MARKET FOR CYTOKINES BY REGION,

THROUGH 2016 ($ MILLIONS) 100

FIGURE 18 GLOBAL MARKET FOR CYTOKINES BY REGION, 2009-

2016 ($ MILLIONS) 100

Other Biological Response Modifiers 100

TABLE 43 GLOBAL MARKET FOR OTHER BIOLOGICAL RESPONSE

MODIFIERS BY REGION, THROUGH 2016 ($ MILLIONS) 101

FIGURE 19 GLOBAL MARKET FOR OTHER BIOLOGICAL RESPONSE

MODIFIERS BY REGION, 2009-2016 ($ MILLIONS) 101

CELL DISSOCIATION REAGENTS 102

TABLE 44 GLOBAL MARKET FOR CELL DISSOCIATION REAGENTS

BY REGION, THROUGH 2016 ($ MILLIONS) 102

FIGURE 20 GLOBAL MARKET FOR CELL DISSOCIATION

REAGENTS BY REGION, 2009-2016 ($ MILLIONS) 102

OTHERS 103

TABLE 45 GLOBAL MARKET FOR OTHERS BY REGION, THROUGH

2016 ($ MILLIONS) 103

FIGURE 21 GLOBAL MARKET FOR OTHERS BY REGION, 2009-2016

($ MILLIONS) 104

CHAPTER FIVE: U S MARKET 105

TABLE 46 U S MARKET FOR CELL CULTURE PRODUCTS,

THROUGH 2016 ($ MILLIONS) 105

FIGURE 22 U S MARKET FOR CELL CULTURE PRODUCTS, 2009-

2016 ($ MILLIONS) 106

MEDIA 106

MARKET OVERVIEW 106

Market Overview (Continued) 107

MARKET REVENUE 108

TABLE 47 U S MARKET FOR CELL CULTURE MEDIA, THROUGH

2016 ($ MILLIONS) 108

FIGURE 23 U S MARKET FOR CELL CULTURE MEDIA, 2009-2016 ($

MILLIONS) 109

SERUM-REQUIRING AND SERUM-FREE MEDIA 109

Market Revenue 110

TABLE 48 U S MARKET FOR SERUM-REQUIRING AND SERUMFREE

MEDIA, THROUGH 2016 ($ MILLIONS) 111

FIGURE 24 U S MARKET FOR SERUM-REQUIRING AND SERUMFREE

MEDIA, 2009-2016 ($ MILLIONS) 111

POWDERED AND LIQUID MEDIA 111

Market Revenue 112

TABLE 49 U S MARKET FOR POWDERED AND LIQUID MEDIA,

THROUGH 2016 ($ MILLIONS) 112

FIGURE 25 U S MARKET FOR POWDERED AND LIQUID MEDIA,

2009-2016 ($ MILLIONS) 113

CLASSICAL AND SPECIALTY MEDIA 113

Market Revenue 114

TABLE 50 U S MARKET FOR CLASSICAL AND SPECIALTY MEDIA,

THROUGH 2016 ($ MILLIONS) 114

FIGURE 26 U S MARKET FOR CLASSICAL AND SPECIALTY MEDIA,

2009-2016 ($ MILLIONS) 114

SERA 115

MARKET OVERVIEW 115

MARKET REVENUE 116

TABLE 51 U S MARKET FOR BOVINE AND OTHER SERA,

THROUGH 2016 ($ MILLIONS) 116

FIGURE 27 U S MARKET FOR BOVINE AND OTHER SERA,

THROUGH 2016 ($ MILLIONS) 117

REAGENTS 117

MARKET OVERVIEW 118

Market Overview (Continued) 119

MARKET REVENUE 120

TABLE 52 U S MARKET FOR CELL CULTURE REAGENTS,

THROUGH 2016 ($ MILLIONS) 120

FIGURE 28 U S MARKET FOR CELL CULTURE REAGENTS, 2009-

2016 ($ MILLIONS) 120

BIOLOGICAL RESPONSE MODIFIERS 121

TABLE 53 U S MARKET FOR BIOLOGICAL RESPONSE MODIFIERS,

THROUGH 2016 ($ MILLIONS) 122

FIGURE 29 U S MARKET FOR BIOLOGICAL RESPONSE

MODIFIERS, 2009-2016 ($ MILLIONS) 122

U S MARKET LEADERS 123

MEDIA 123

Serum-Free Media 123

TABLE 54 U S MARKET SHARES OF SERUM-FREE MEDIA, 2010 (%) 123

FIGURE 30 U S MARKET SHARES OF SERUM-FREE MEDIA, 2010

(%) 124

Serum-Requiring/Containing Media 124

TABLE 55 U S MARKET SHARES OF SERUM-CONTAINING MEDIA,

2010 (%) 124

FIGURE 31 U S MARKET SHARES OF SERUM-CONTAINING

MEDIA, 2010 (%) 125

Powdered Media 125

TABLE 56 U S MARKET SHARES OF POWDERED MEDIA, 2010 (%) 125

FIGURE 32 U S MARKET SHARES OF POWDERED MEDIA, 2010 (%) 126

Liquid Media 126

TABLE 57 U S MARKET SHARES OF LIQUID MEDIA, 2010 (%) 126

FIGURE 33 U S MARKET SHARES OF LIQUID MEDIA, 2010 (%) 127

Classical Media 127

TABLE 58 U S MARKET SHARES OF CLASSICAL MEDIA, 2010 (%) 127

FIGURE 34 U S MARKET SHARES OF CLASSICAL MEDIA, 2010 (%) 128

Specialty Media 128

TABLE 59 U S MARKET SHARES OF SPECIALTY MEDIA, 2010 (%) 128

FIGURE 35 U S MARKET SHARES OF SPECIALTY MEDIA, 2010 (%) 129

SERA 129

Bovine Sera 129

TABLE 60 U S MARKET SHARES OF BOVINE SERA, 2010 (%) 129

FIGURE 36 U S MARKET SHARES OF BOVINE SERA, 2010 (%) 130

Other Sera 130

TABLE 61 U S MARKET SHARES OF OTHER SERA, 2010 (%) 130

FIGURE 37 U S MARKET SHARES OF OTHER SERA, 2010 (%) 131

REAGENTS 131

Biological Response Modifiers 131

TABLE 62 U S MARKET SHARES OF BIOLOGICAL RESPONSE

MODIFIERS, 2010 (%) 132

FIGURE 38 U S MARKET SHARES OF BIOLOGICAL RESPONSE

MODIFIERS, 2010 (%) 132

Cell Dissociation Reagents 132

TABLE 63 U S MARKET SHARES OF CELL DISSOCIATION

REAGENTS, 2010 (%) 133

FIGURE 39 U S MARKET SHARES OF CELL DISSOCIATION

REAGENTS, 2010 (%) 133

Other Reagents 133

TABLE 64 U S MARKET SHARES OF OTHER REAGENTS, 2010 (%) 134

FIGURE 40 U S MARKET SHARES OF OTHER REAGENTS, 2010 (%) 134

CHAPTER SIX: END USERS 135

MARKET SHARE OF APPLICATIONS 135

TABLE 65 GLOBAL MEDIA, SERA AND REAGENT MARKET SHARES

BY END USER, 2010 (%) 136

FIGURE 41 GLOBAL MEDIA, SERA AND REAGENT MARKET

SHARES BY END USER, 2010 (%) 136

RESEARCH SEGMENT 136

RESEARCH SEGMENT (CONTINUED) 137

RESEARCH SEGMENT (CONTINUED) 138

MARKET REVENUE 139

TABLE 66 GLOBAL SALES OF MEDIA, SERA AND REAGENTS IN

THE RESEARCH SEGMENT, THROUGH 2016 ($ MILLIONS) 139

FIGURE 42 GLOBAL SALES OF MEDIA, SERA AND REAGENTS IN

THE RESEARCH SEGMENT, 2009-2016 ($ MILLIONS) 140

PRODUCTION SEGMENT 140

PRODUCTION SEGMENT (CONTINUED) 141

MARKET REVENUE 142

TABLE 67 GLOBAL SALES OF MEDIA, SERA AND REAGENTS IN

THE PRODUCTION SEGMENT, THROUGH 2016 ($ MILLIONS) 142

FIGURE 43 GLOBAL SALES OF MEDIA, SERA AND REAGENTS IN

THE PRODUCTION SEGMENT, 2009-2016 ($ MILLIONS) 143

CONTRACT SEGMENT 143

CONTRACT SEGMENT (CONTINUED) 144

MARKET REVENUE 145

TABLE 68 GLOBAL SALES OF MEDIA, SERA AND REAGENTS IN

THE CONTRACT SEGMENT, THROUGH 2016 ($ MILLIONS) 146

FIGURE 44 GLOBAL SALES OF MEDIA, SERA AND REAGENTS IN

THE CONTRACT SEGMENT, 2009-2016 ($ MILLIONS) 146

OTHERS SEGMENT 146

MARKET REVENUE 147

TABLE 69 GLOBAL SALES OF MEDIA, SERA AND REAGENTS IN

THE OTHERS SEGMENT, THROUGH 2016 ($ MILLIONS) 148

FIGURE 45 GLOBAL SALES OF MEDIA, SERA AND REAGENTS IN

THE OTHERS SEGMENT, 2009-2016 ($ MILLIONS) 148

CHAPTER SEVEN: PATENT ANALYSIS 149

PATENTS BY YEAR 149

TABLE 70 NUMBER OF U S PATENTS ISSUED BY YEAR, 2007 TO

OCT 2011 150

FIGURE 46 U S PATENTS ISSUED BY YEAR, 2007 TO OCT 2011 (%) 150

PATENTS BY TYPE 150

TABLE 71 PATENTS BY TYPE FOR MEDIA, SERA AND REAGENTS

USED IN BIOTECHNOLOGY, 2007-2011 151

FIGURE 47 PATENTS BY TYPE FOR MEDIA, SERA AND REAGENTS

USED IN BIOTECHNOLOGY, 2007-2011 (NO OF PATENTS) 151

PATENTS BY COMPANY 151

TABLE 72 U S PATENTS ISSUED FOR MEDIA, SERA AND

REAGENTS IN BIOTECHNOLOGY BY COMPANY, 2007 TO OCT

2011 (NO) 152

PATENTS BY COUNTRY 153

TABLE 73 U S PATENTS ISSUED FOR MEDIA, SERA AND

REAGENTS USED IN BIOTECHNOLOGY BY COUNTRY, 2007 TO

OCT 2011 (NO) 153

TABLE 74 SHARES OF U S PATENTS ISSUED FOR MEDIA, SERA

AND REAGENTS USED IN BIOTECHNOLOGY BY COUNTRY,

2007-OCT 2011 (%) 154

PATENTS BY ASSIGNEE 154

TABLE 75 U S PATENTS ISSUED FOR MEDIA, SERA AND

REAGENTS USED IN BIOTECHNOLOGY BY TYPE OF END USER,

2007 TO OCT 2011 (NO) 154

CHAPTER EIGHT: THE CURRENT SITUATION 155

REGIONAL MARKETS 155

UNITED STATES 155

EUROPE 156

ASIA 156

EMERGING MARKETS 157

TRENDS AND ISSUES IN THE CELL CULTURE MARKET 157

GLOBAL ECONOMY 157

INCREASED RESEARCH AND DEVELOPMENT BUDGET 157

TABLE 76 R&D BUDGETS OF TOP 10 COMPANIES IN 2009 AND 2010

($ BILLIONS) 158

GROWING DEMAND AND RICH PIPELINE OF

BIOTHERAPEUTICS 158

RESEARCH ON THERAPEUTIC VACCINES 159

BIOMEDICAL RESEARCH 160

STEM CELL RESEARCH 160

GOVERNMENT POLICIES ON RESEARCH 160

INNOVATIONS 161

ETHICAL AND ANIMAL WELFARE ISSUES 161

REGULATORY ISSUES 162

USE OF HUMAN BLOOD ALTERNATIVES 162

MERGERS, ACQUISITIONS AND ALLIANCES 163

SHIFT TOWARD CONTRACT MANUFACTURING 163

CHAPTER NINE: COMPANY PROFILES 164

ADVANCED BIOTECHNOLOGIES INC 164

AFFYMETRIX 164

AMRESCO LLC 165

ATHENA ENVIRONMENTAL SCIENCES INC 165

ATLANTA BIOLOGICALS INC 166

BD BIOSCIENCES 167

BIORECLAMATION INC 167

BOVOGEN BIOLOGICALS PTY LTD 168

CELL APPLICATIONS INC 168

CELL CULTURE TECHNOLOGIES GMBH 169

CLONTECH LABORATORIES INC 170

EQUITECH-BIO INC 170

GEMINI BIO-PRODUCTS 171

GENEX INDIA BIOSCIENCES PVT LTD 171

HIMEDIA LABORATORIES 172

INVITROGEN CORP 172

IRVINE SCIENTIFIC 173

J R SCIENTIFIC INC 174

LONZA 174

MEDIATECH INC 175

MEDOX BIOTECH INDIA PVT LTD 175

MILLIPORE CORP 176

MP BIOMEDICALS 177

PAA LABORATORIES 178

PEPROTECH INC 178

PROMOCELL GMBH 179

QUALITY BIOLOGICAL INC 179

R&D SYSTEMS 180

ROCHE APPLIED SCIENCES 181

SERA LABORATORIES INTERNATIONAL LTD 181

SERACARE LIFE SCIENCES INC 182

SIGMA-ALDRICH 182

STEMCELL TECHNOLOGIES 183

STEMCELLS INC 183

THERMO FISHER SCIENTIFIC INC 184

TICO EUROPE 185

VALLEY BIOMEDICAL PRODUCTS AND SERVICES INC 186

APPENDIX: ABBREVIATIONS 187

ABBREVIATIONS 187

ABBREVIATIONS (CONTINUED) 188

ABBREVIATIONS (CONTINUED) 189

To order this report:

In Vitro Diagnostic Industry : Global Markets for Media, Sera and Reagents in Biotechnology -- Focus on the U.S.

More Market Research Report

Check our Industry Analysis and Insights

__________________________

Contact Nicolas: nicolasbombourg@reportlinker.com US: (805)-652-2626 Intl: +1 805-652-2626

SOURCE Reportlinker
COPYRIGHT 2012 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Article Type:Company overview
Date:May 31, 2012
Words:4772
Previous Article:Group 1 Automotive Assessing Hail Damage To Oklahoma City Dealerships.
Next Article:The Sterling Group Completes the Sale of Roofing Supply Group, LLC.
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters